Tempus AI Guides FY Revenue to $1.6B-$1.61B, Swings to Q2 Profit
TEM is trading near its 52-week low of $40.77 (7.7% above the low).
Summary
Tempus AI delivered Q2 revenue of $389.5M, up 22% year-over-year, slightly beating estimates, and swung to a GAAP net profit of $12.3M from a loss a year ago. Adjusted EBITDA hit $42.7M. The company set full-year revenue guidance at $1.6B-$1.61B, signaling confidence in the growth trajectory. This follows the $1.5B Personalis acquisition announced July 20, which expands Tempus's oncology diagnostics capabilities. The profit inflection and strong guidance suggest the AI-driven precision medicine platform is scaling efficiently.
At the time of this announcement, TEM was trading at $43.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8B. The 52-week trading range was $40.77 to $104.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.